【Announcement Selection】The wholly-owned subsidiary of Ruichuang Micro-Nano was included in the SDN list by OFAC of the United States, and ST Shimao failed to pay the accumulated debt of 12.1 billion yuan on time

Look at the announcement, Xiao E is the first to report!

Ruichuang Micro-Nano: A wholly-owned subsidiary is included in the SDN list by OFAC in the United States

Ruichuang Micro-Nano (688002) announced on the evening of May 5 that recently, the company has noticed that the U.S. Department of the Treasury's OFAC (Office of Foreign Assets Control) has included the company's wholly-owned subsidiary, Yantai Arrow Optoelectronics Technology Co., Ltd. (hereinafter referred to as "Arrow Optoelectronics"), on the SDN list (Specially Designated Nationals List).

The company's wholly-owned subsidiary, Arrow Optoelectronics, focuses on the R&D and manufacturing of infrared imaging technology and products, with completely independent intellectual property rights, and is committed to providing professional and competitive infrared thermal imaging products and industry solutions for global customers.

Arrow Optoelectronics does not have overseas branches, and the company is evaluating the impact of its subsidiary, Arrow Optoelectronics, being added to the SDN list, and will develop effective countermeasures.

The inclusion of Arrow Optoelectronics in the SDN list will not affect the business development of the company and other subsidiaries, and the overall impact on the company is controllable. At present, the company's operation and financial situation are normal, the orders in hand are sufficient, and the market development work is progressing in an orderly manner.

ST Shimao: Failed to pay the accumulated debt of 12.055 billion yuan on time

ST Shimao announced on the evening of May 5 that as of April 30, 2024, the company and its subsidiaries had failed to pay a total of 12.055 billion yuan of open market debts, non-public market bank and non-bank financial institution debts.

Guosheng Financial Holdings: The absorption and merger of Guosheng Securities has completed the corresponding internal approval procedures of the company

Guosheng Financial Holding issued an announcement on abnormal fluctuations in stock trading, in view of the fact that Guosheng Securities is a wholly-owned subsidiary of the company, the absorption and merger will not have a substantial impact on the company's operation, and will not have a significant impact on the assets and liabilities within the scope of the company's consolidated statements.

The company's absorption and merger has completed the corresponding internal approval procedures of the company, and it needs to be approved by the relevant regulatory authorities before it can be implemented, and there are uncertainties about whether the matter can obtain relevant approvals, when the relevant approvals will be obtained, and the final implementation completion time.

Shengbang Security: It is planned to hold no less than 60% of the equity of Tianyu Yunan with no more than 30 million yuan

Shengbang Security announced that based on the company's strategic layout and business development needs in satellite Internet security, the company intends to use its own funds of no more than 30 million yuan to hold no less than 60% of the equity of Beijing Tianyu Yun'an Technology Co., Ltd. (hereinafter referred to as "Tianyu Yun'an").

Hongyu shares: Some directors and executives plan to reduce their holdings of no more than 1.55% of the company's shares

Hongyu shares announced that directors Liu Qiujie, Liu Zhihong and senior management Zhang Lijie plan to reduce their holdings of no more than 2.03 million shares of the company by centralized bidding or block trading within 6 months after 15 trading days from the date of disclosure of the shareholding reduction plan, accounting for 1.55% of the company's total share capital.

BYD: Sales of new energy vehicles in April were 310,000 units, compared with 210,000 units in the same period last year

BYD announced that the sales volume of new energy vehicles in April was about 313,200 units, compared with about 210,300 units in the same period last year. In April, a total of 41,011 new energy passenger vehicles were sold overseas, and the total installed capacity of power batteries and energy storage batteries for new energy vehicles in April was about 12.559GWh, and the cumulative installed capacity in 2024 was about 42.295GWh.

BAIC Blue Valley: The cumulative sales of subsidiaries from January to April were 13,004 units, a year-on-year decrease of 34.59%

BAIC Blue Valley announced that its subsidiary, Beijing New Energy Automobile Co., Ltd., sold 2,882 vehicles in April, compared with 4,768 units in the same period last year, and the cumulative sales volume from January to April was 13,004 units, a year-on-year decrease of 34.59%.

Cialis: Sales of Cialis automobiles increased by 742.47% year-on-year in April

Cialis announced that the sales of new energy vehicles in April were 27,868, a year-on-year increase of 302.89%. Among them, Sailis sold 24,878 vehicles, a year-on-year increase of 742.47%.

Ruby Lee: The product sales situation in April was better

Hongbaoli recently said at the performance briefing that the product sales situation in April was better. In addition, in response to the rumor that "monoisopropanolamine and diisopropanolamine have recently increased in price", Hongbaoli responded that the company's prices of monopropanolamine and diisopropanolamine are currently relatively stable.

Shenlian Biotech: Swine fever vaccine was approved for new veterinary drug registration

Shenlian Biotech announced that after review by the Ministry of Agriculture and Rural Affairs, the company's swine fever genetic engineering subunit vaccine (CHO-133D) was approved as a new veterinary drug, and the "New Veterinary Drug Registration Certificate" was issued. This product is a product jointly developed and declared by the company and Beijing Zhonghai Biotechnology Co., Ltd. and other units, which can be used to prevent swine fever.

Weixinkang: The subsidiary obtained the drug registration certificate of potassium aspartate injection

Weixinkang announced that recently, Yangpu Jingtai Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the "Drug Registration Certificate" for potassium aspartate injection approved and issued by the State Drug Administration. Potassium aspartate injection is an electrolyte supplement for hypokalemia caused by various causes.

Sinovac Pharmaceutical: Passed the EU GMP certification

Sinovac Pharmaceutical announced that it recently received the "Drug GMP Certificate" issued by the Norwegian Medicines Agency in accordance with the relevant regulations of the European Medicines Agency, and the certified product: paclitaxel for injection (albumin-bound type) (5mg/ml).

Paclitaxel for injection (albumin-bound) is the mainstream first-line drug recommended by the European Society of Medical Oncology guidelines for the treatment of metastatic pancreatic cancer and non-small cell lung cancer.

According to the GMP mutual recognition system between EU member states, the GMP certification indicates that the certified production line has met the EU GMP standards, and the company's paclitaxel (albumin-bound) products for injection have EU market access qualifications.

After passing the GMP certification this time, paclitaxel for injection (albumin-bound) is still subject to EU marketing authorization application (MAA) approval before marketing in the EU.

Sai Microelectronics: The production capacity of the Swedish production line has increased several times compared with before the acquisition

Sai Microelectronics said on the interactive platform on May 5 that the characteristics and strengths of the Swedish production line lie in process development and pilot test, and the proportion of process development business has been high, and its capacity utilization rate in 2023 is 46.87%, which is similar to the level before the acquisition, but the production line capacity has increased several times compared with before the acquisition, which is also the main reason for the continuous growth of its revenue and profit.

In addition, in response to the rumor that "Celex Microsystem Technology (Beijing) Co., Ltd. recently delayed the payment of wages for one month and only paid 70% of the basic salary", Sai Microelectronics responded that the information was not true, and the salaries of employees of the company's parent company and domestic and foreign subsidiaries were paid on schedule.

Guosheng Technology: The subsidiary won the bid for a photovoltaic module procurement project of no less than 500 million yuan

Guosheng Technology announced that Anhui Guosheng New Energy, a secondary holding subsidiary, won the bid for the photovoltaic module procurement project of CGN Yantai Zhaoyuan 400MW offshore photovoltaic project (HG30), with a total bid price of not less than 500 million yuan.

Jiaxun Feihong: The company participated in the relevant communication support of Chang'e-6

Jiaxun Feihong said on the interactive platform on May 5 that the company participated in the relevant communication support of Chang'e-6.

Puli Pharmaceutical: Obtained Saudi Arabia GMP certificate

Puli Pharmaceutical announced that it recently received a GMP certificate issued by the Saudi Arabian Food and Drug Authority (SFDA). The acquisition of the GMP certificate of the Saudi Arabian Food and Drug Administration indicates that the company's related products and production lines meet the requirements of Saudi Arabian GMP.

Huasu shares: Wantou Industry plans to reduce its holdings of no more than 1% of the company's shares

Huasu Co., Ltd. announced that Anhui Wantou Industrial Investment Co., Ltd. holds about 418 million shares of the company, accounting for 11.91% of the company's total share capital. Wantou Industry intends to reduce its holdings by a total of no more than about 35.074 million shares, not more than 1% of the company's total share capital.